Stem Cell Therapy for ARDS

What This Article Covers

Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that leaves the air sacs flooded and starved of oxygen, and it remains one of critical care's toughest problems even with the best ventilator support. Researchers have spent over a decade testing whether mesenchymal stem cells (also called mesenchymal stromal cells, or MSCs) can calm the runaway inflammation that drives ARDS and help damaged lung tissue recover. This article walks through what the actual clinical trial evidence shows — including a genuinely encouraging signal from pooled trial data — while being direct about the individual large trials that have not hit their mark, and about the fact that no MSC product is FDA-approved for ARDS today.

How It's Thought to Work

MSCs are adult stem cells, most often sourced from bone marrow, umbilical cord tissue, or fat, that are grown in a lab and infused intravenously. They aren't thought to work by directly replacing damaged lung cells. Instead, the theory is that MSCs act like a mobile repair crew: once infused, they release signaling molecules that dial down the inflammatory storm inside injured lungs, help clear excess fluid from the air sacs, and support the lung's own barrier and repair mechanisms. This mechanism has held up well in laboratory and animal studies, which is a big part of why MSCs generated so much excitement as a potential ARDS treatment, including a wave of new trials launched specifically for COVID-19-related ARDS.

What the Evidence Shows

Here's the encouraging part first: a 2023 meta-analysis in Critical Care pooled data from 13 randomized controlled trials totaling 655 ARDS patients and found that MSC treatment was associated with meaningfully lower 28-day mortality than control treatment (odds ratio 0.66), with no increase in adverse events across the pooled studies. That's a real, statistically significant signal worth taking seriously — it's the strongest evidence yet that this approach has genuine therapeutic potential, and it's why the field hasn't walked away from MSCs despite some frustrating individual trial results.

Those individual trial results are the necessary counterweight. The largest COVID-19 ARDS trial to date, published in the American Journal of Respiratory and Critical Care Medicine (222 patients), was stopped early after an interim analysis found no significant mortality benefit (37.5% MSC vs. 42.7% control) and no improvement in ventilator-free days. The REALIST-COVID trial (60 patients) found its MSC product safe but saw no improvement in oxygenation and a longer duration of mechanical ventilation in the treated group. Most recently, the phase 2b STAT trial — a rigorous, double-blind, placebo-controlled study of 120 ARDS patients — found no physiologic or clinical benefit from a single MSC dose at any mortality timepoint through 180 days. And the original phase 2a START study, which established that MSC infusion was safe with no immediate adverse respiratory or hemodynamic events, nonetheless recorded numerically higher 28- and 60-day mortality in the MSC group versus placebo in that small sample.

Across essentially every controlled trial, MSC infusion has been well tolerated with no signal of drug-related serious harm — that consistency on safety is itself meaningful. What hasn't consistently followed is a clear efficacy benefit in any single well-powered trial, even as the pooled data hints that a real effect may exist, possibly concentrated in patient subgroups researchers haven't yet learned to identify reliably.

Who Might Be a Candidate

MSC therapy for ARDS remains investigational, not a standard or approved treatment. Right now, the only realistic way to access it is through a clinical trial. People who may want to look into enrolling include:

• Adults with moderate-to-severe ARDS, including ARDS caused by COVID-19 or other infections, who are being treated at an academic medical center running an active trial
• Patients (or families making decisions on their behalf) interested in contributing to research even without a guarantee of personal benefit
• Anyone evaluating a clinic or program claiming to offer "stem cell treatment for ARDS" outside of a registered clinical trial, who should treat that claim with significant skepticism

Bottom Line

The idea that mesenchymal stem cells could help the body repair ARDS-damaged lungs remains one of the more scientifically credible frontiers in critical care research, and the pooled trial data showing a mortality benefit is a genuinely hopeful sign. But hope and hedged optimism are different from a proven treatment: the largest, most rigorous individual trials run to date have not shown a clear clinical benefit, and no MSC or other stem cell product is FDA-approved for ARDS, COVID-19, or any lung disease. The FDA has explicitly warned that clinics marketing stem cell treatments for these conditions are offering unapproved products. For now, MSC therapy for ARDS belongs in clinical trials, not clinical practice.